Role of cell-cycle-regulatory proteins in mesangial cells and glomerular disease
The proliferation of glomerular mesangial cells is a common feature of many glomerular diseases. The cell cycle of mesangial cells is under the control of a large number of humoral factors which either promote or suppress mitogenesis and cell proliferation. Recently Shankland et al. [3] demonstrated that mesangial cell proliferation in the Thy-1 model of experimental messuch as growth factors induce D-type cyclins. D-type cyclins assemble angial proliferative glomerulonephritis is associated with CDK4 and CDK6, and this cyclin-D-CDK complex phos-with an upregulation of cyclin A and an increase in phorylates retinoblastoma protein (pRb). INK4 family (including the expression and activity of CDK2. They also showed p16Ink4a, p15Ink4b, p18Ink4c and p19Ink4d) is specific for the G 1
CDKs, that the normal glomerulus has high endogenous CDK4 and CDK6, and inhibits the kinase activity of the cyclin D/CDK4-CDK6 complexes on pRb. KIP family is constituted by expression of the CKI, p27Kip1, which decreases with p21cip1, p27Kip1, and p57Kip2. Their inhibitory action concerns a large the initiation of the mesangial cells' proliferative range of cyclin-CDK complexes involved in the G 1 and S phases.
response and then normalizes with the resolution of the mesangial cells' proliferation [3] . Further, they near the G 1 /S transition, assembling with a distinct found that p21cip1 has low levels of expression in the catalytic subunit, CDK2. Cyclin E-CDK2 is also cru-normal rat glomerulus, but that resolution of mesangial cial for G 1 -to-S phase transition. Since cyclin E, unlike cell proliferation is associated with an increase in cyclin D1, is essential for entry into the S phase in p21cip1 expression [3] . They also observed using mammalian cells lacking functional pRb, it regulates p27Kip1, knockout mice that the absence of p27Kip1 was a transition different from that promoted by cyclin D. associated with a marked increase in the severity of The cyclin E-CDK2 complex may contribute to pRb the glomerular response to injury induced by antiphosphorylation late in the G 1 phase. GBM antibody-induced crescentic glomerulonephritis [4] . Recently, in our own investigation of the mechan-
CDK inhibitors
isms of the cell-cycle regulation of rat mesangial cells, we produced adenovirus vectors containing coding sequences of cyclin D1, p16Ink4a, and p21cip1, and Cyclin-dependent kinases (CDKs) are negatively controlled by two distinct groups of inhibitory pro-investigated whether transfer of these genes changes serum-and PDGF-induced proliferation of rat mesteins, the cyclin-dependent kinase inhibitors (CKIs) (Figure 1 ). The first group, inhibitors of the cdk4 angial cells [5] . Our findings suggested that p16Ink4a significantly and p21cip1 moderately inhibited the pro-(INK4) family (including p16Ink4a, p15Ink4b, p18Ink4c and p19Ink4d ) is specific for the G 1 CDKs, CDK4 and liferation of mesangial cells induced by growthpromoting factors [5] . We also demonstrated that CDK6, and inhibits the kinase activity of the cyclin D/CDK4-CDK6 complexes on pRb. Using two-hybrid endothelin-1 induced cyclin D1 expression and stimulated CDK4 activity and cell cycle progression via interaction screening with CDK4 as a probe, p16Ink4a was first discovered as a 16-kDa protein which associ-A-type receptor in rat mesangial cells [6 ] . These effects were regulated by expression of cyclin D1, p16Ink4a, ates with cdk4. By binding to CDK4 or CDK6 but not to cyclins or other known cdks, recombinant p21cip1, and phosphorylatable form of pRb.
Schoecklmann et al. [7] reported that phosphorylation p16Ink4a forms a binary complex lacking kinase activity. p15Ink4b, the synthesis of which is induced by TGF-b, of pRb is required for PDGF-induced mesangial cell proliferation in vitro. Prevention of pRb phosphorylseems to be a mediator of TGF-b-mediated cell cycle arrest. Furthermore, p18Ink4c inhibits CDK6 phos-ation by TGF-b or by overexpressing the nonphosphorylated form of pRb inhibits mitogen-induced phorylation and activation by CAK.
The second CKI family comprises p21cip1, p27Kip1, mesangial cell proliferation in vitro [6, 7] . and p57Kip2 ( Kip family). Their inhibitory action concerns a large range of cyclin/CDK complexes involved
Cell-cycle regulation of tubular cells and acute
in the G 1 and S phases. p21cip1, which is induced in renal failure (ARF ) models part by p53, is upregulated by senescence, DNA damage, and cellular differentiation. p21cip1 forms quarternary complexes with CDKs, cyclins, and DNA replication and proliferation of renal tubular cells occur during recovery from ischaemic acute renal PCNA. Its inhibitory action preventing CDK from phosphorylation depends on the stoichiometry of the failure (ARF ). During this process, quiescent renal cells in the G 0 phase enter a new phase of the cell components. As in the case of p15Ink4b, p27Kip1 also cycle, the G 1 phase. Some of the immediate early genes renal mass, and protein feeding. The mechanism of such as c-fos and Egr-1 are reported to increase during renal hypertrophy is largely unknown. Recently two the G 0 /G 1 transition after ischaemic ARF [8] . groups reported that the mechanism of tubular hyperHowever, the types of cell-cycle-related genes expressed trophy is pertinent to cell-cycle-related genes. Franch in the G 1 /S phase during recovery from ARF are not et al. [13] reported that TGF-b converts the EGFfully known.
induced growth response from hyperplasia to hyperRecently Megyesi et al. [9] demonstrated increased trophy by causing cell cycle arrest at the restriction expression of p21cip1 in three different models of ARF point in late G1 via reduction of the cdk2/cyclin E (ischaemia, ureteral obstruction, and cisplatin adminis-kinase activity. Wolf et al. [14] reported that tration). They also demonstrated that p21cip1 expres-angiotensin II stimulated p27Kip1 protein expression in sion is localized exclusively in cells of thick ascending LLC-PK1 cells, and that this induction of CDK inhiblimbs and distal convoluted tubules in ARF. They itor is a necessary prerequisite for the subsequent suggested that p21cip1 gene transcription is a general generation of tubular hypertrophy. Our preliminary response to renal injury and could be a key determinant experiments demonstrated also that Ang II caused of cell fate in the cells in which it is expressed [9] . hypertrophy of LLC-PK1 cells with increment of They also found that p21cip1 knockout mice display a p27Kip1 protein level, and that overexpression of p21cip1 more rapid onset of the physiological signs of acute and p27Kip1 using adenovirus caused hypertrophy in renal failure, develop more severe morphorogical LLC-PK1 cells. On the other hand, overexpression of damage, and have a higher mortality [10] . They specu-p16Ink4a did not cause hypertrophy [15] . late that the induction of p21cip1 after acute renal Although these findings from the cell culture system damage by cisplasin is a protective event for kidney are informative, the in vivo mechanisms of renal hypercells [10] . They demonstrated that cisplatin administra-trophy are more complex and need to be clarified both tion caused kidney cells to start entering the cell cycle in the cell culture system and animal models of renal [10] . However, cell-cycle progression is inhibited in hypertrophy. wild-type mice, whereas kidney cells in the p21cip1 knockout mice progress into S-phase. They propose that p21cip1 protects kidneys damaged by cisplatin by Summary preventing DNA-damages cells from entering the cell cycle, which would otherwise result in death from
Our understanding of the cell-cycle mechanisms has either apoptosis or necrosis [10] .
Park et al.
[11] also demonstrated that the proliferat-progressively advanced in the past few years. Cyclins ive index increased in the kidney section, and that the and cyclin-dependent kinases play major roles as positmRNA and protein levels of cyclins D1, D3 and B; ive cell-cycle regulatory proteins and CDK inhibitors; the mRNA levels of cyclin A; the protein levels of while the Kip family and INK4 family are negative CDK4 and CDK2; and the activities of CDKs (CDK4, regulatory proteins in mesangial cells and renal tubular CDK2 and cdc2) all increased in the outer medullae cells. An understanding of the cell cycle is essential for of kidneys after ischaemic injury. They suggest that the rational design of novel pharmacotherapeutic the temporal induction of proliferative activity in outer approaches to suppress the excessive proliferation of medullary tubules was closely linked with the mesangial cells in glomerular disease and hypertrophic cyclin/CDK system for regeneration of kidney after tubular disease. ischaemic injury [11] .
We also demonstrated the expression and regulation of cyclin D1, cyclin D3, CDK4, p21cip1, and p27Kip1 References during recovery from ischaemic ARF [12] . We found that cyclin D1, cyclin D3, and CDK4 increased after New aspects concerning the role of catecholamines in the pathogenesis of glomerular diseases Introduction that sympathetic nerve stimulation or addition of norFor many years catecholamines are known to particip-adrenaline decreases the diameter of the glomeruli [5] . ate in the regulation of glomerular blood flow and A decrease in K f after sympathetic nerve stimulation microcirculation, mainly by influencing cellular func-may at least partially be due to a reduction of glomertions of the renal vascular and the glomerular mesang-ular surface area. In mesangial cells, noradrenaline ium [1] . Until recently knowledge about the actions of increases the uptake of Ca2+ and induces a cell contraccatecholamines on cells from the glomerular filtration tion [6, 7] . Thus, it has been suggested that noradrenabarrier is, due to their unique localization, limited. line-induced mesangial cell contraction might decrease These cells, i.e. podocytes and glomerular endothelial K f by a reduction of the capillary surface area [7] . cells are probably involved in the control of glomerular However, noradrenaline might not only contract meshaemodynamics and filtration. Especially the podocyte angial cells but also podocyte foot processes, which seems to be an important regulator of glomerular are known to possess a rich contractile apparatus [8] . functions: it stabilizes the glomerular architecture, Noradrenaline-induced contraction of foot processes maintains a large filtration surface, and serves as an might also lead to a reduced capillary surface area and effective barrier to plasma proteins [2] . Very recently decreased K f . It appears difficult to prove this Mundel et al. successfully propagated differentiated hypothesis, but a detection of noradrenaline-induced podocytes in cell culture, thus allowing the study of changes of podocyte function may support its validity. biological properties of these cells in vitro [3] . This article discusses new insights about the influence of Catecholamines modulate cellular functions of catecholamines on podocyte function and the possible glomerular cells biological and pathophysiological relevance of the Very recently, we investigated the influence of catecholfindings.
amines on cellular functions of differentiated cultured podocytes from a mouse carrying a transgene for a
The physiological role of catecholamines in the thermosensible variant of the SV40 T-antigen [9] .
glomerulus
Podocytes from this mouse grown at 37°C exhibit Stimulation of renal sympathetic nerves produces a a differentiated morphology and express specific frequency-dependent decrease in the glomerular filtra-immunological markers of podocytes in vivo [3] . tion rate, due to an increased glomerular arteriolar Figure 1 shows an overview of catecholamine-mediated resistance, a decreased glomerular hydraulic pressure cellular signalling in podocytes: in cultured podocytes gradient, and a decreased glomerular ultrafiltration noradrenaline and the a 1 -adrenoceptor agonist phenylephrine increase the intracellular calcium activity ([Ca2+] i ) [9] . in podocytes, suggesting that nor-induced acute renal failure adrenaline-induced Ca2+ influx in podocytes is not mediated by a -type Ca2+ channel, but may be due The findings discussed above indicate that noradrenaline directly influences podocyte function. This might to the activation of a receptor-operated or storecontrolled Ca2+ or non-selective cation channel. In not only play a role under physiological conditions but may also be important for the pathogenesis of subsequent experiments, we demonstrated that phenylephrine, noradrenaline, and the b-adrenoceptor agon-renal diseases such as acute renal failure (ARF ).
The pathophysiological mechanisms of ARF are not ist isoproterenol activate a Cl− conductance in podocytes leading to depolarization [9] . The rank clearly understood, but renal vasoconstriction, tubular obstruction, back leakage of filtrate, and decrease in order of potency for the adrenoceptor agonists in depolarizing podocytes was isoproterenol>noradrena-glomerular capillary permeability are involved.
Podocytes maintain a large filtration surface through line>phenylephrine. A specific b 2 -adrenoceptor antagonist inhibited the effect of isoproterenol, indicating the slit membranes and are responsible for~40% of the hydraulic resistance of the glomerular filtration that podocytes do not only express a 1 -adrenoceptors but also b 2 -adrenoceptors. The depolarization of barrier [13] . They might therefore be involved in the decrease of capillary permeability occurring in ARF. podocytes in response to isoproterenol is probably mediated by an increase in cAMP, because forskolin, It has been reported that infusion of noradrenaline into the renal artery of dogs induces ARF, which was a direct activator of adenylate cyclase, also depolarized podocytes and the addition of isoproterenol not due to vasoconstriction, tubular leakage, or tubular obstruction [14] . However, after infusion of noradrenato podocytes resulted in an increase in cAMP. The physiological significance of the b 2 -adrenoceptor line filtration barrier damage has been observed.
Podocytes showed marked abnormalities including substances such as prostaglandines or oxygen radicals. flattening of cell body and obliteration of foot processes [14] . Although a subsequent study using the same (ii) The role of protein kinase C in noradrenalinemediated effects. Familial Mediterranean fever ( FMF ) is a fascinating of cutaneous and large tree vasculitis suggest that vascular inflammation can occur. Most of the attacks disease which has been recognized recently [1] . The mode of inheritance was disputed, and finally defined are two to three days long and the patients are well between them. Patients commonly have leucocytosis as autosomal recessive with variable penetrance and high gene frequency in affected populations. FMF with neutrophilia, increased erythrocyte sedimentation rate and increased serum concentrations of acute phase mainly affects populations of Mediterranean origin: Arabs, Armenians, Druses, non-Ashkenazy and less proteins.
Despite ignorance regarding the exact cause and frequently Ashkenazy Jews, Turks, and probably many others. Clinical signs reflect two processes: 1) acute pathological mechanisms leading to FMF, clinicians have a very efficient treatment which prevents the inflammatory crisis with fever and localized inflammation, and 2) amyloidosis of the AA type representing recurrence of most of the inflammatory crises and amyloid deposition [4] . Colchicine is the standard the most severe manifestation of the disease. The pathological mechanisms associated with these two treatment for FMF, even though long-term use of colchicine is not innocuous. Recent genetic advances processes are still poorly understood. The gene whose mutations are responsible for FMF has now been offer the theoretical opportunity for the long-term discovery of more specific molecules. cloned and this should result in improved understanding of the disease [2, 3] .
FMF as a familial disorder: a new success of FMF is a non-periodic acute polyserositis sensitive positional cloning to colchicine
Four decades of research have aimed at identifying a The most common sign of FMF is acute peritoneal specific defect for FMF in the inflammatory reaction. inflammation resulting in severe abdominal pain and The most convincing abnormality likely to be implichigh fever. One out of three patients with these signs ated in the mechanisms of FMF is a tissue-specific undergoes surgical intervention. The inflammatory lack of a putative inhibitor of a proinflammatory process can involve all serous cavities: pleura, pericar-protein of the complement pathway, the C5a fraction dium and testicular vaginalis. However, this tropism is [5] . This inhibitor is still not well characterized. relative and other tissues can also be involved, such as The first step, primary location of the gene, was articular synovia, skin and muscle. Some observations achieved in 1992 [6 ] groups independently and simultaneously discovered MEFV. It encodes a protein named marenostrin by reminds us that fever and inflammation are necessary to fight against infection. the French group, referring to mare nostrum, the Latin name of the Mediterranean Sea, and pyrin by the American group, referring to pyros, the Greek name for fever [2, 3] . The gene is 10 kb long, consists of 10 exons, and its mRNA is 3.7 kb long. The latter seems FMF and amyloidosis: what is the missing link?
to be specific for the neutrophil. The genomic sequence of MEFV predicts a basic protein consisting of 781 Amyloidosis of the AA type is the major problem of amino acid residues and shares some similarities with FMF. There is compelling evidence that amyloidosis proteins of the RoRet or B30.2 family, to which belong is not only a complication of the inflammatory response several transcription factors. Thus, marenostrin/pyrin but is rather, at least in part, an associated phenommay be a neutrophil-specific transcription factor. Of enon. Firstly, there is no close link between the severity course, this has to be demonstrated by further cellular of the inflammatory crisis and the outcome of amyland molecular biology studies. Four missense muta-oidosis. Indeed, some patients present with amyloidosis tions were identified in the distal part of exon 10 of without any previous inflammatory event or subclinical the marenostrin/pyrin gene, in about 75% of the crises (so-called phenotype II ). Secondly, it was clearly patients selected for the genetic study. We can easily demonstrated that colchicine prevents the development hypothesize that a lot of other mutations will be of amyloidosis in every patient, whereas the discovered in years to come, associated with the varied inflammatory crises were not completely suppressed. forms of clinical presentation and across the diverse Thirdly, the prevalence of amyloidosis varies among populations. The availability of a genetic test which the Mediterranean populations. The role of the identifies these four mutations will improve clinical marenostrin/pyrin protein in the amyloid pathway is diagnosis, and utilization of the colchicine treatment.
not as obvious. Some authors have suggested that MEFV encodes the human equivalent of the amyloid enhancing factor (AEF ), an important molecule implicated in experimental amyloidosis, which is not
Marenostrin and the Mediterranean
yet well characterized [7, 8] . Further studies would help to determine whether marenostrin/pyrin plays a direct Haplotype analysis of the disease-bearing chromo-role in the mechanisms of amyloidosis and, therefore, somes showed the existence of one or more founder whether it is the missing link between inflammation effects in all the populations studied thus far. Of major and amyloidosis. Conversely, as is suggested by some interest is the fact that two of these four mutations, authors, the absence of the mythic 'missing link' is not and the corresponding haplotype, are found in different a hindrance to the coherence of the Darwinian theory populations. For instance, the M694V mutation, which of evolution. If that is the case, other genetic or is strongly predominant in non-Ashkenazy Jews is also environmental factors are necessary to explain all the present in Arabs, Armenians and Turks, suggesting a aspects of amyloidosis in FMF patients. common origin for a part of these populations. These data provide new perspectives regarding the genetics of these populations. , reported an 8 month old boy who presented Firstly the disease still carries a significant burden of with HUS; both he and his healthy 3 year old brother morbidity and mortality. Death rate, estimated at 9% had 5-10% normal levels of factor H, inherited in an and 29% in two recent studies [3,4], may be 'over autosomal recessive fashion from consanguineous paroptimistic' because of the inclusion of undefined num-ents, each of whom had approximately 50% normal bers of patients with the closely related thrombotic levels. Roodhooft et al. in 1990 [13] described a female thrombocytopenic purpura ( TTP) which is more infant who suffered three episodes of HUS (including amenable to treatment. Secondly with the exception of an ultimately fatal recurrence following renal transplasma exchange few treatments have been demon-plantation) with 48% normal levels of factor H probably strated to be effective.
inherited from her unaffected father who had 34% We propose a complement-based theory of micro-normal levels. Pichette et al. in 1994 [16] reported a angiopathy, critically involving complement factor H, family in whom two siblings suffered HUS: one died at and speculate on possible future treatments.
an early age from diarrhoeal-associated HUS (E. coli serotype 0119:B14) and the other suffered three episodes of HUS from the age of 19 and was shown to have 5%
Complement and HUS
normal factor H levels. An asymptomatic sister also Evidence implicating the complement system, and in had 5% levels and several members of the extended particular the alternative pathway, exists for all forms family had approximately 50% levels. of HUS. Low C3 levels were first described in D+HUS in the early 1970s and it has also been reported that What does complement factor H do?
persistently low levels are predictive of a poor prognosis Factor H is the most important plasma bound regu- [5, 6 ] .These findings have been subsequently confirmed lator of the alternative pathway [21] ; it does this firstly, and further evidence of alternative pathway activation by binding with C3b, preventing the formation of the presented in studies which demonstrated increased C3bBb (C3 convertase) complex and accelerating the breakdown products of C3 and factor B [7] [8] [9] . dissociation of Bb from the active C3 convertase (so In D−HUS C3 is sometimes deposited in the renal called decay-accelerating activity) [22, 23] ; secondly, by arterioles, and C3 levels are often depressed [10] . In acting as a cofactor for factor I, a serine protease, recurrent D−HUS profound depression of C3 is seen, which degrades C3b by cleaving the alpha chain of particularly during relapses, but also in disease-free C3, converting it into the major opsonic form, iC3b intervals [11] [12] [13] . An association with the hypo-[23]; and thirdly, by distinguishing between activator morphic fast allele of C3 has been reported in D−HUS and non-activator surfaces [24] .
[14], but no difference in complement activity between Factor H is a plasma protein produced primarily the alleles has been demonstrated [15] . In familial by the liver with a concentration of approximately 300-600 mg/l. Deficiency or malfunction causing HUS D−HUS alternative pathway activation has also been is therefore consistent with the therapeutic response to reported [12, 16, 17] .
plasma exchange. In a recent study we have found that in three families HUS maps to a region of chromosome 1q containing
The interaction of factor H and renal endothelium
It is interesting that recurrent episodes of thrombotic microangiopathy are not seen in HUS patients under-going dialysis, and that bilateral nephrectomy can in studies we should like to propose a unifying theory of microangiopathy, based on deficiency or dysfunction acute HUS reverse the manifestations [25, 26 ] . Moreover renal transplantation is often associated with recurrent of complement control molecules. HUS. Can factor H be implicated in such tropism? Ca2+ receptor are the molecular lesions underlying of the mechanism by which parathyroid cells sense inherited disorders of systemic Ca2+ homeostasis, such changes in the concentration of extracellular Ca2+.
Prospects for treatment What other diseases have been associated with
as autosomal dominant hypocalcaemia, familial benign The Ca2+ receptor is a relatively new member of the hypocalciuria hypercalcaemia, and neonatal severe G protein-coupled receptor superfamily and shares limited sequence homology with the metabotropic glu-primary hyperparathyroidism [2] . Furthermore these studies underscore the key role played by the Ca2+ administration of NPS R-568 [6 ] . By activating the Ca2+ receptor and decreasing secretion of PTH, calcireceptor in regulating plasma levels of PTH and Ca2+. Thus the Ca2+ receptor is a novel molecular target for mimetic compounds directly target the underlying hormonal imbalance leading to the signs and symptoms new drugs that may prove useful in treating bone and mineral-related disorders. One obvious therapeutic of primary hyperparathyroidism. In patients with this disease, a calcimimetic compound could conceivably application for compounds that activate the Ca2+ receptor is the treatment of diseases such as hyper-constitute a stand-alone therapy.
A small study in renal dialysis patients with secondparathyroidism that are characterized by chronically elevated circulating levels of PTH.
ary hyperparathyroidism has also demonstrated the ability of NPS R-568 to lower plasma levels of PTH rapidly [7] . Elevated levels of PTH are just one of the problems, however, in the hyperparathyroidism that
What are calcimimetic agents?
is secondary to renal failure and, in this setting, it is anticipated that therapy with calcimimetic comLigands that mimic or potentiate the effects of extra-pounds will be adjunctive. Supplementation with cellular Ca2+ at the Ca2+ receptor have been termed 1,25-dihydroxyvitamin D 3
will be necessary to maincalcimimetics, and there are at least two pharmacolo-tain proper systemic Ca2+ homeostasis and it will also gically distinct types. Type I calcimimetic compounds be important to control plasma phosphate levels. are agonists, whereas type II calcimimetics are positive allosteric modulators that increase the sensitivity of the Ca2+ receptor to activation by extracellular Ca2+.
All known type I calcimimetics are inorganic or organic Potential benefits from the use of calcimimetic polycations that lack the appropriate pharmaceutical agents properties necessary for in vivo testing. In contrast, the first-generation type II calcimimetic compounds, typi-Hypocalcaemia, in addition to lowered levels of fied by NPS R-568, are small organic compounds that 1,25-dihydroxyvitamin D 3 and hyperphosphataemia, are potent and selective activators of the Ca2+ receptor has long been known to stimulate hyperplasia of the and are suitable for in vivo testing. Calcimimetic com-parathyroid glands. The Ca2+ receptor might mediate pounds trick the parathyroid cell into sensing a hyper-this effect of extracellular Ca2+ on cellular proliferacalcaemic condition when in fact plasma levels of Ca2+ tion. Indeed, daily treatment of rats with a calcimimetic are normal. Calcimimetic compounds therefore offer a compound prevented proliferation of parathyroid cells means of rapidly and directly suppressing the secretion caused by subtotal nephrectomy [8] . If compounds, however, prevent parathyroid cell proliferation despite low levels of 1,25-dihydroxyvitamin An early issue in the development of calcimimetic D 3 and chronic hyperphosphataemia. Thus, at least compounds for hyperparathyroidism was whether the in rats it appears that Ca2+ receptor activation can Ca2+ receptors in adenomatous or hyperplastic tissues override the stimuli to cellular proliferation triggered are 'normal'. So far, comparisons between normal and by lowered 1,25-dihydroxyvitamin D 3 and elevapathological parathyroid tissues have not revealed any ted phosphate levels. structural differences in the Ca2+ receptor cDNA [3] .
One appealing aspect of cotherapy with a calcimiWhat has been noted consistently, however, is an metic compound lies in its potential to treat secondary apparently lower level of expression of the Ca2+ recep-hyperparathyroidism without the risk of causing hypertor in hyperplastic and adenomatous parathyroid tis-calcaemia. Another is the ability to titrate the dose of sues [4, 5] . Nonetheless there appear to be sufficient calcimimetic compound rapidly to achieve the desired quantities of Ca2+ receptor remaining to regulate PTH level of PTH. One or both of these features are lacking secretion, because calcimimetic compounds have now in the treatment options currently available. In many been shown to suppress plasma levels of PTH rapidly patients with secondary hyperparathyroidism, calcitriol in patients with primary or secondary hyper-simply fails to lower plasma levels of PTH, and in parathyroidism.
many others it does so only at doses that cause hypercalcaemia and/or hyperphosphataemia. Some of the newer 'noncalcaemic' vitamin D analogues might
Initial clinical experience with calcimimetics
overcome the limitations imposed by bouts of hypercalcaemia and/or hyperphosphataemia. It is not known if these new analogues will improve the percentage of In postmenopausal women with primary hyperparathyroidism, there is a time-and dose-dependent reduction patients that respond to treatment, which varies from 30 to 70% following treatment with calcitriol. So far in plasma levels of PTH and Ca2+ following the oral Nephrol Dial Transplant (1998) 13: Editorial Comments 1925 there have not been any 'non-responders' following treatment with NPS R-568, but the patient population studied is small and the effects of calcimimetic compounds have not been tested in patients with severe hyperparathyroidism.
Differences between treatment with vitamin D metabolites and calcimimetics
There is, however, a fundamental difference between the mechanism of action of vitamin D metabolites (or Fig. 1 . Contrasting effects of vitamin D analogues and metabolites, phosphate binders) and calcimimetic compounds that and calcimimetic compounds on plasma levels of PTH. The freenable the latter to alter plasma PTH levels in a quency, waveform, and amplitude of plasma PTH levels can be varied by altering the pharmacokinetic properties and dosing regimen manner not previously possible. Vitamin D metabolites of the calcimimetic compound. Omitted for the sake of clarity are act genomically to decrease the synthesis of PTH. In pulsatile (episodic) changes in plasma levels of PTH, which occur those instances where calcitriol does lower plasma with a frequency of about seven per hour, and small circadian levels of PTH, the effects are slow in onset (often variations. weeks to months) and persist for weeks after treatment is stopped. In contrast, calcimimetic compounds act on the mechanism (the Ca2+ receptor) that regulates PTH that set them apart from all other current therapthe moment-to-moment secretion of hormone.
ies. Whether such compounds will eventually become Calcimimetic compounds can lower plasma levels of a mainstay in the management of hyperparathyroidism PTH within 20 min after oral dosing, and levels return is still to be determined. At the very least, compounds to pre-dosing levels within 24 h. These different mechthat act on the Ca2+ receptor will constitute important anisms of action result in very different profiles pharmacological probes to discern the functions of the of change in plasma levels of PTH (Figure 1 ).
Ca2+ receptor and the skeletal effects of dynamic Calcimimetic compounds allow, for the first time, daily changes of plasma PTH levels in normal and pathointermittent decreases in plasma levels of PTH. The logical conditions. amplitude (or maximal decrease) in PTH levels is largely dependent on the dose of compound. The frequency and the waveform of the changes in plasma References It is the ability of calcimimetic compounds to cause NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53: 448-453 both short-and long-term changes in plasma levels of Introduction type 1 diabetic patients. Presumably due to the size of the stratified sample could we demonstrate a clear Blood pressure and glycaemic control are well established association between AER and protein intakes [8] , factors influencing the development and progression of which former smaller studies were not able to identify. diabetic nephropathy. However, regarding the involveMore detailed analysis revealed that the trend of ment of protein intake in the aetiology of renal disease, AER to increase with higher intakes of protein was state-of-the-art lectures mostly summarize current evidlargely due to higher levels of AER in those individuals ence with a question mark. Indeed, the role of protein who consumed >20% of their dietary energy as prointake in the prevention or progression of nephropathy tein. For type 1 diabetic persons with protein intakes remains ambiguous, with many questions still awaiting up to 20%, mean AER remained <20 mg/min, but in conclusive answers. Recent findings from large-scale individuals with a protein consumption >20% of food intervention studies in non-diabetic subjects indicate that energy intake mean AER levels were in the microalbuthe effort to reduce protein intake is rewarded by only minuric range (Á20 mg/min) [8] . small benefits for the progression of nephropathy [1, 2] .
In comparison to the key approaches for an effective However, studies in people with clinically overt diabetic prevention of diabetic nephropathy-the optimization nephropathy suggest that the situation may be different of blood pressure and glycaemic control-the associin individuals with type 1 diabetes [3,4]. Is protein intake ation of protein intake to the progression of nephrothus more relevant for diabetic nephropathy? Hence, are pathy is much weaker. This is commonly raised as an low protein diets effective in slowing its progression? In argument against an early consideration of protein that case, can an early introduction of low protein diets restriction. However, in the EURODIAB IDDM even prevent renal disease [5, 6 ] , which individuals with
Complications Study we could show that the trend of type 1 diabetes are so prone to develop [7] ? Should we, AER to increase with higher dietary protein intakes therefore, promote a low protein diet for individuals with was particularly pronounced in patients with hypertendiabetes mellitus and if so at which stage of the disease? sion and/or elevated HbA1c values [8] . Should we advise type 1 diabetics to restrict their protein intake when a macroalbuminuria is diagnosed, or already when they present a microalbuminuria or even long Protein consumption is two times higher than before that? How low do low protein diets need to be? required Or conversely: which upper limit of protein intake should not be exceeded? Is there a specific level above which Debates on the relevance of protein restriction for the protein intakes need to be discouraged? progression of renal disease often relate to the efficacy of a diet providing 0.8 g protein/kg body weight per day in comparison to a diet with 0.6 g protein/kg body
Some new aspects of the protein issue
weight. Meanwhile the vast majority of European individuals with type 1 diabetes consume more than Recent evidence from individuals with type 1 diabetes twice as much dietary protein. In the EURODIAB suggests that protein intakes do indeed matter for the IDDM Complications Study average protein intake development and/or progression of renal disease was 1.5±0.5 g protein per kg body weight, which because they are associated with urinary albumin excreamounts to 17.6±3.5% of total energy intake. About tion rates (AER). We found a significant relation to one out of four type 1 diabetic patients consumed levels of AER for both total and animal protein intakes >20% of protein [8, 9] . Throughout Europe animal (% of energy) in type 1 diabetic patients from the protein provided~70% of the protein consumption EURODIAB IDDM Complications Study. This crossand protein intakes of the type 1 diabetic individuals sectional, clinic-based study in 31 European centres, were uniformly higher than commonly observed in the was designed to explore risk factors for diabetic comgeneral population of the respective country. Once patients presented micro-or macroalbuminuria intake: particularly persons with macroalbuminuria, 1927 but also subjects with microalbuminuria consumed of the patients with diabetic nephropathy will eventumore total protein and more animal protein than ally suffer and die [13] . Thus, a concomitant reduction individuals with normoalbuminuria [8] . of saturated fat intake is a meaningful 'side effect'. The main dietary sources for animal protein require particular attention. The consumption of meat should be restricted to one serving per day (~125 g). Also, Should current recommendations for protein intake cold meat and cheese need specific consideration be updated?
and should only be consumed in small amounts. Furthermore, two daily servings of milk or milk prodThe Diabetes and Nutrition Study Group (DNSG) of ucts (e.g. one yoghurt and one glass of milk) are the European Association for the Study of Diabetes sufficient to meet nutritional needs. The consumption and the American Diabetes Association (ADA) recom-of large amounts of curd-as recommended to indimend a protein intake ranging between 10% and 20% viduals with diabetes mellitus until the early 80s in of total energy to people with diabetes mellitus. order to achieve satiety-should no longer be advised, Patients with incipient or manifest nephropathy should even if it is low in dietary fat. Instead, the consumption be advised to reduce their protein intake to the lower of protein from vegetable sources, which are also rich end of this range (0.7-0.9 g/kg body weight). The in dietary fibre, should be encouraged. Associations felt that not enough scientific evidence was available to generally recommend a lower protein intake for all individuals with diabetes [10,11].
The rationale for the recommendation not to exceed References a protein intake of 20% was largely based on the consumption commonly observed in the general popu- The acute renal effects of Angiotensin II receptor blockers Introduction the control of glomerular haemodynamics, thus being responsible for the differences between the two classes Angiotensin II (ANG II ) has a wide range of effects of ANG II inhibiting drugs. These results support to on resistance vessels, kidney and heart through type 1 a certain extent the hypothesis that ATA are less likely and type 2 (AT1, AT2) receptors [1] . Effects through than ACEI to induce acute renal failure as an unwanted AT1 receptors on vessels, glomeruli and tubules of the side-effect in patients. Controlled trials comparing the kidney include vasoconstriction, cell proliferation, and two classes of inhibitors of the renin system in man matrix protein synthesis. Activation of AT2 receptors with conditions such as renal artery stenosis or volume leads to vasodilatation, inhibition of cell proliferation depletion are as yet lacking. and presumably programmed cell death (apoptosis).
One should keep in mind that the contribution of The latter effects oppose to a certain extent the conbradykinin to the control of glomerular haemosequences of a AT1 receptor stimulation.
dynamics differs vastly between species; furthermore, Recently developed non-peptide antagonists for type the study mentioned above investigated rats with very 1 receptors of angiotensin II (ATA) will be more and severe volume depletion [2] . In other rat models with more widely used in the treatment of patients with diabetic hyperfiltration and with experimental nephritis primary or renal hypertension, and possibly in patients results were comparable to the dehydrated animals. In with heart or kidney failure. Another class of drugs the diabetic rat with high GFR [3], ACEI were more that blunt the effects of the renin-angiotensin system effective than an ATA to acutely normalize GFR. through inhibition of angiotensin II formation are the Again, a bradykinin antagonist inhibited the action of ACE inhibitors (ACEI ), which potently increase the ACEI in this situation. In experimental nephritis bradykinin levels as well. Much is known about the [4], an ATA was much less effective than an ACEI to acute effects of ACEI on the kidney. Some of these reduce proteinuria. Despite those consistent differences actions are desirable like antiproteinuria and natriuesis, of ATA and ACEI on acute renal changes in rats, there others are unwanted, most notably acute falls in glomare many reports about quite comparable long-term erular filtration rate (GFR).
renal effects of those two types of angiotensin inhibitWhat about the acute renal effects of the new ATA ory drugs [3, 5, 6 ] but this is outside the scope of the and how do they compare with the ACEI? present communication.
Studies in animals Studies in men
Early experimental studies with ATA in rats with renal How about patients? Doig studied severely volumediseases offered some surprises. In a number of settings, depleted healthy volunteers and showed a clear-cut, the acute renal effects of ATA proved to be clearly reversible decrease in GFR by almost 50% when an different from ACEI. Thus, in rats with severe volume ATA was added [7] . This study was controlled by depletion, resistance of the efferent glomerular arteriole placebo but not by ACEI or other antihypertensive was reduced to a much greater extent by ACEI than agents. Controlled trials comparing ATA and ACEI in by ATA. In parallel, the intraglomerular hydraulic patients at risk of acute renal failure are as yet lacking pressure and the single-nephron GFR fell with the except for the ELITE study [8] . More than 700 patients ACEI, being maintained on the ATA. The action of with heart failure were randomly assigned to an ATA the ACEI was blunted by blockade of bradykinin or an ACEI; a similar incidence (about 10% in each receptors [2] . Bradykinin, the metabolism of which is group) of an acute decrease of GFR was established. impaired renal function showed an identical decrease in GFR with captopril (50 mg) or with losartan occurs during ATA treatment safe, or are the high circulating levels of angiotensin II potentially harmful (200 mg). In one case report, however, a transplanted patient tolerated ATA without an decrease in GFR in some circumstances? Is bradykinin, the tissue concentration of which is likely to be increased during while acute renal failure developed during ACEI treatment [9] .
ACEI treatment, an important cofactor in ameliorating end-organ damage in e.g. hypertension? Or should we How about proteinuria? In the absence of long-term studies in men, the effect of ATA on protein excretion assume that the putative role of bradykinin for cough and angioneurotic oedema is a sufficient cause to may to a certain extent be a surrogate marker for nephroprotective potential of these drugs. Gansevoort eventually eliminate ACEI altogether? Further research to address these questions on the chronic effects of et al.
[10] demonstrated similar effectiveness of ATA and ACEI in patients losing several grams of protein ATA could possibly yield guidelines for differential therapies with ATA and ACEI, depending on the per day on a low-sodium diet. The data indicate that the antiproteinuric action of the ATA was slower in pathophysiology of the disease and the individual circumstances of the patient to be treated. onset than that of ACEI. There also appear to be subtle differences in the natriuretic effect which are quite apparent in rats [11] . In patients the latter action of ACEI is sustained over several days and quite References What are the conclusions for patient management? The appropriate blood pressure control in diabetes tensin II seems to play a central role. This notion finds support in data showing that ACE inhibitors and (ABCD) trial was designed to test the primary hypothesis that intensive blood pressure control, as com-possibly also angiotensin II receptor antagonists, cause important reduction in proteinuria and disease progrespared to usual blood pressure control, prevents or slows down progression of diabetic nephropathy, sion, more than explained by lowering of blood pressure [2] . On the other hand, a large body of evidence neuropathy, retinopathy and cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM ). In indicates that optimal blood pressure control per se to values of less than 140/90 mmHg reduces albuminuria a recent publication [1] data on a secondary end-point were reported, i.e. the incidence of (fatal or non-fatal ) and attenuates the rate of loss of GFR [4] independent of the type of antihypertensive used. myocardial infarction in a subgroup of ABCD patients who had hypertension. In this cohort a significantly Consequently, in patients with diabetic nephropathy, as in patients with non-diabetic renal disease, optimal higher incidence was noted amongst those assigned to the short acting calcium channel blocker (CCB) blood pressure control is mandatory [5] . Nisoldipine compared to those assigned to receive the ACE-inhibitor Enalapril: 25 vs 5 events during 5 years Monotherapy or combination of antihypertensive of follow-up, yielding a risk ratio of 9.5.
agents
The data will undoubtedly lead to uncertainty and doubts concerning the proper use of CCBs in the Monotherapy with low or standard doses is the ideal treatment of renal patients, particularly those with way to control sustained hypertension. However, some diabetic nephropathy. I shall try to interpret critically clinical studies evaluated to what extent normalization this important nephrological topic.
of blood pressure can be achieved with monotherapy in patients without and with renal disease. It was noted that target diastolic blood pressure could be reached
Control of arterial pressure in diabetic nephropathy
in no more than 37% of cases [6 ] and this is particularly true for hypertensive patients with diabetic or nonArterial hypertension and renal disease are closely diabetic renal disease. In fact, in many studies of interrelated in many ways: hypertension may precede patients with serum creatinine levels between 2 and renal disease, but also be caused by, or aggravated by, 4 mg/dl, up to four classes of antihypertensive drugs renal disease: it is a strong predictor of all causes of were required [2, 4] . Therefore, appropriate combinamorbidity and mortality and, last but not least, it tions of different antihypertensive drugs are necessary accelerates progression of renal disease. The risk of to obtain appropriate lowering of blood pressure withdeveloping nephropathy, one of the most common out incurring inacceptable side effects. In the ABCD causes of end-stage renal disease (ESRD) in many trial, 30-50% of hypertensive patients with NIDDM Western countries, seems to be linked, at least in part, required one or two additional antihypertensive drugs to an inherited predisposition to hypertension [2] . In [1] . addition, there is overwhelming evidence from experimental models and clinical observations that elevated blood pressure is a potent progression promotor. Calcium channel blockers in diabetic nephropathy Systemic hypertension probably acts through elevation of filtration pressure; this results from loss of glomer-CCBs are a heterogeneous group of agents interfering ular autoregulation in the diabetic milieu. Elevated with transmembrane calcium influx. They are widely glomerular fluid shear stress is thought to initiate a used because they are effective antihypertensive drugs. cascade of events ultimately leading to glomerulo-The antihypertensive action seems to be associated, sclerosis and tubulo-interstitial scarring [3] . Angio-amongst others, with the property of CCBs to act as non-specific post-receptor antagonist of several vasoCorrespondence and offprint requests to: Prof. Pietro Zucchelli, constrictive agents, including angiotensin II. In addiMalpighi Department of Nephrology, Policlinico S. OrsolaMalpighi, Via P. Palagi 9, I-40138 Bologna, Italy. tion, CCBs have antiproliferative and cytoprotective properties and retard experimental atherosclerosis [7] .
Finally, in the ABCD trial, a group on placebo treatment was not studied. Thus, we do not know In experimental models as well as in humans with renal diseases, particularly in patients with diabetic whether CCBs were just less effective than ACE inhibitors or truly deleterious. To interprete the absolute nephropathy, the result of the administration of CCBs on progression has remained controversial. In fact, rates of myocardial infarction or cardiovascular death, one has to compare the observations with data pubCCBs cause preferential afferent vasodilation and impairment of renal autoregulation. As a result, a lished in literature. The rate of myocardial infarction in the ABCD study was by no means greater than greater proportion of systemic blood pressure is transmitted to the glomerular vascular bed [8] . The anti-might be expected in such a high risk population. Their high risk is illustrated by the fact that 33% had LVH proteinuric and nephroprotective effects of CCBs are directly related to their ability to normalize systemic by electrocardiography. An illustrative example of the risk to draw the wrong conclusion from analyzing a blood pressure. Many of the discrepancies in experimental and clinical studies can be explained as the secondary end-point is provided by the recently published AIPRI (Ace Inhibition in the Progressive Renal result of different levels of blood pressure reduction. Moreover, CCBs are heterogenous: their effect to block Insufficiency) trial. This was a randomized, multicentre study that demonstrated the value of ACE inhibitors the five subclasses of L-type calcium channels differs, and this point may also be responsible for some of the in slowing the progression of renal disease. An unexpected difference of mortality, i.e. of a secondary enddiscrepancies.
In conclusion, CCBs are only nephroprotective if point, was noted: nine deaths occurred during the 3-year follow-up in the benazepril group and only one adequate blood pressure control has been achieved. Possibly, non-dihydropyridine CCBs offer better renal in the placebo group. This result was actually explained by an abnormally low mortality rate in the placebo protection compared to dihydropyridine CCBs. In a randomized study on 52 patients with NIDDM, dia-group. In fact, the recently published extension study concerning the large majority of patients who had betic nephropathy and hypertension, similar levels of blood pressure control were achieved with either ACE originally been randomized to benazepril or placebo showed that the difference in mortality had completely inhibitors or non-dihydropyridine CCB. Both agents significantly reduced proteinuria and slowed down the disappeared after a median total follow up of 6.6 years.
In contrast, the long-term beneficial effect of benazepril progression of renal disease to a similar extent [7] .
So in the past it was argued that there are many on progression was completely confirmed [11] . good reasons for combining ACE inhibitors and CCBs. The arguments include not only the fact that additional
Conclusion
antihypertensive action can be obtained with possibly less side effects, but also the above mentioned point that additional beneficial effects may be achieved.
In patients with diabetic nephropathy as well as in patients with non-diabetic renal disease, proteinuria and preservation of renal function are primarily a Do we have to modify this statement after the function of blood pressure reduction. Because of their
ABCD report?
documentated effect in improving renal survival and reducing cardiovascular events, ACE inhibitors (with A peculiar clustering of adverse cardiovascular out-or without diuretics) should be used as the firstline comes was observed in hypertensive diabetic patients, agent in patients with diabetes and hypertension. Longin the ABCD study [1] , as well as in one other acting CCBs should be added, however, as a second randomized trial [9] . These observations would be step if target blood pressure values cannot be achieved consistent with the idea that in these high risk patients, with the administration of ACE inhibitors alone. CCBs cause an excess of adverse events.
Several observations, however, militate against this interpretation. First, many recent case control studies References and several prospective randomized placebo-controlled contrary, the relative risk of death tended to be lower.
Am J Kidney Dis 1996; 27: Second, the ABCD study found an increased incidence between the two groups.
Zucchelli's comment on our recent New England ABCD Trial had been followed for 5 years, and was Journal of Medicine (NEJM ) article entitled 'The effect within one year of the closure of the study on June 30, of nisoldipine as compared to enalapril on cardiovas-1998. The members of the DSMC did not feel that the cular outcomes in patients with non-insulin dependent safety of the hypertensive diabetic patients should be diabetes and hypertension' made some key points. jeopardized by following them on nisoldipine for the Certainly the control of arterial blood pressure in remaining year of the study. diabetic patients is important in preventing or slowIt is correct that the termination of the comparison ing progression of diabetic complications including between nisoldipine vs enalapril in the hypertensive nephropathy. The optimal level of blood pressure to cohort was based on a morbidity result, i.e. MIs, rather prevent or slow diabetic complications however has than mortality endpoint (10 deaths in the nisoldipine not been established. The appropriate blood pressure vs 5 deaths in the enalapril group, P=NS ). As we control in diabetes (ABCD) clinical trial is based on emphasized in the NEJM article, the number of MIs the hypothesis that the accepted upper limit of normal per year in the nisoldipine group over the 5-year blood pressure, 140/90 mmHg, may not be optimal to follow-up of the hypertensive cohort was not significprevent or slow the progression of diabetic complica-antly greater than historic controls published in the tions given the underlying abnormalities which occur literature in type 2 diabetic patients. Thus, this finding in the capillary basement membranes throughout the would support a cardioprotective effect of the angiobody. A secondary hypothesis of the ABCD trial was tensin converting enzyme inhibitor, enalapril, rather that the level of blood pressure, intensive vs moderate, than any deleterious effect of the calcium channel rather than the first line of antihypertensive agent, blocker, nisoldipine. However, since we did not have namely nisoldipine vs enalapril, would be significant. a placebo control this must be a tentative conclusion. As reported in our NEJM paper, the secondary hypo-It should be emphasized, however, that a placebo thesis of equivalency between nisoldipine and enalapril control would not be ethical in a hypertensive diabetic was rejected. After 5 years of follow-up in the hyper-group of patients. tensive cohort the Data and Safety Monitoring Before submitting our paper for consideration of Committee (DSMC ) of the ABCD trial recommended publication to the NEJM, we analysed many potential that the nisoldipine patients be changed to enalapril factors which could explain the difference in MIs because of the difference in the incidence of myocardial between the nisoldipine and enalapril treated patients infarctions (MI ) between the two groups (nisoldipine in the hypertensive cohort rather than the drugs per se. (25 of 235 patients) vs the enalapril (5 of 235 patients). In this regard, the only differences in the baseline We have emphasized in the paper that this was a characteristics were a slight, but statistically significant, secondary endpoint. Whether a primary or secondary higher mean HDL concentration and lower prevalence endpoint, however, it can always be argued that a of abnormal ankle-to-brachial indices, as evidence of significant finding might not persist with a longer less peripheral vascular disease, in the nisoldipine follow-up. The hypertensive diabetic cohort in the group. These differences were therefore in the wrong direction to account for the observed difference in MIs Correspondence and offprint requests to: R. W. Schrier, University of between the nisoldipine and enalapril-treated hyper-Introduction findings (in particular when examined by immunohistology and electron microscopy) can allow with IgA nephropathy (IgAN ) is the most common type of some likelihood the differentiation between the relative glomerulonephritis in the Western world [1] . Up to 25% contribution of dysfunction due to recurrent disease of patients develop end-stage renal failure. When such and other reasons, in particular chronic alloreactive patients receive a kidney graft, up to 60% will experience damage. Clinically manifest recurrent IgAN is often a histological recurrence of the disease. Until recently, associated with persistent microhaematuria and proit has been assumed that such recurrence of IgAN after teinuria exceeding 0.5 g/day as well as the demonstratransplantation is a relatively benign condition and tion of mesangioproliferative glomerulonephritis, i.e. hardly ever results in progressive graft failure. This not just recurrent mesangial IgA deposits, upon graft assumption was derived from case reports and early biopsy. Even when all these findings are present, howstudies on this subject [2, 3] . Several recent studies [4] [5] [6] [7] ever, the available data on recurrent IgAN need to be have re-investigated the above notion and will be the interpreted with the caveat in mind, that other mechantopic of this review. However, before embarking in isms may have amplified recurrence-related graft details of these more recent studies, it appears useful to damage in an additive or even synergistic manner. first analyse how clinically relevant recurrence of IgAN These considerations also imply that caution should can be identified in renal transplant patients.
be applied when interpreting studies, in which few Chronic renal graft dysfunction has a multifactorial clinical data are provided [9] [10] [11] . origin and results from both immunological mechanisms, in particular chronic allograft rejection, as well as non-immune mechanisms such as hypertensive How frequent is recurrence of IgA damage, hyperlipidaemia, cyclosporine nephrotoxicity, glomerulonephritis in the graft? in 46 transplanted IgAN patients followed for 3-183 Table 1 . Summary of recent studies on the clinical relevance of recurrent IgAN after transplantation
